HeartSciences Inc. filed a Form 8-K to furnish a press release from Fortitude Mining Holdings, Inc., dated August 20, 2026, detailing its second quarter 2026 financial and operating results. The filing highlights that Fortitude reported $20.9 million in revenue and an Adjusted EBITDA of $8.5 million for the period ended June 30, 2026. Additionally, the press release notes that on August 12, 2026, Fortitude purchased approximately $1,000,000 worth of HeartSciences common stock in a private placement at a negotiated VWAP of $2.43 per share, acquiring 411,522 shares. This investment brings Fortitude's ownership stake to approximately 9.4% and supports HeartSciences' operating expenses ahead of the expected closing of their proposed business combination in the second half of 2026. HeartSciences Inc. operates in the healthcare information technology industry, advancing ECG/EKG management through artificial intelligence.

HeartSciences Inc. filed an amendment to its Form 8-K to include Fortitude Mining Holdings, Inc.'s unaudited interim financial statements for the six months ended June 30, 2026 and 2025. This filing supplements the initial announcement of a definitive merger agreement between HeartSciences and Fortitude, an all-stock transaction expected to close in the second half of 2026 where Fortitude is the accounting acquirer. The financials show Fortitude reported $40.1 million in mining revenues and a net loss of $14.2 million for the period, alongside a $10.3 million impairment charge on mining equipment due to sustained declines in digital asset prices. HeartSciences Inc. operates in the healthcare technology industry, developing artificial intelligence-enhanced electrocardiography solutions.

HeartSciences Inc. consummated a private placement sale of 411,522 shares of common stock to Fortitude Mining Holdings, Inc. on August 12, 2026, for an aggregate purchase price of approximately $1 million at $2.43 per share. This transaction represents a 22% premium to the closing market price and provides working capital ahead of the expected closing of the proposed business combination with Fortitude later in 2026. The merger agreement's exchange ratio remains unchanged, and no additional shares will be issued to Fortitude equity holders as a result of this investment. Following the purchase, Fortitude holds approximately 9.4% of HeartSciences’ outstanding common stock. HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence.

HeartSciences Inc. filed a preliminary proxy statement and issued a press release regarding its proposed all-stock business combination with Fortitude Mining Holdings, Inc., announced in June 2026. The transaction involves the issuance of approximately 107.6 million shares of new Class V Common Stock to Digital Currency Group, resulting in pro forma combined shareholders' equity of $70.0 million. HeartSciences reported no meaningful revenue for fiscal year 2026 ending April 30, 2026, with cash and equivalents of approximately $1.7 million. The filing also outlines a proposal to authorize the Board to implement a reverse stock split within a range of 1-for-2 to 1-for-5 if necessary for Nasdaq listing compliance. HeartSciences operates in the healthcare information technology sector, focusing on AI-integrated electrocardiography solutions.

HeartSciences Inc. filed its fiscal 2026 Annual Report on Form 10-K and announced it expects to file a preliminary proxy statement regarding its proposed business combination with Fortitude Mining Holdings, Inc. The company expects to issue its fiscal 2026 earnings release and a business update early next week. HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence.

HeartSciences Inc. entered into a merger agreement on June 23, 2026, involving Fortitude Mining Holdings, Inc. and its subsidiaries to facilitate a transaction where HeartSciences becomes the sole managing member of the surviving company. In connection with the merger, the company amended the employment agreement for CFO Danielle Watson to include severance benefits and granted her 25,000 restricted stock units that vest over one year. HeartSciences is a medical technology company focused on cardiac health diagnostics.